Enzyme Inhibitor: Enzyme Activators Bind To Enzymes and Increase Their Enzymatic Activity
Enzyme Inhibitor: Enzyme Activators Bind To Enzymes and Increase Their Enzymatic Activity
Enzyme Inhibitor: Enzyme Activators Bind To Enzymes and Increase Their Enzymatic Activity
The binding of an inhibitor can stop a substrate from entering the enzyme's
active site and/or hinder the enzyme from catalyzing its reaction. Inhibitor
binding is either reversible or irreversible. Irreversible inhibitors usually
react with the enzyme and change it chemically (e.g. via covalent bond
formation). These inhibitors modify key amino acid residues needed for
enzymatic activity. In contrast, reversible inhibitors bind non-covalently and
different types of inhibition are produced depending on whether these
inhibitors bind to the enzyme, the enzyme-substrate complex, or both.
Enzyme inhibitors also occur naturally and are involved in the regulation of
metabolism. For example, enzymes in a metabolic pathway can be inhibited
by downstream products. This type of negative feedback slows the
production line when products begin to build up and is an important way to
maintain homeostasis in a cell. Other cellular enzyme inhibitors are proteins
that specifically bind to and inhibit an enzyme target. This can help control
enzymes that may be damaging to a cell, like proteases or nucleases. A well-
characterised example of this is the ribonuclease inhibitor, which binds to
ribonucleases in one of the tightest known protein–protein interactions.[1]
Natural enzyme inhibitors can also be poisons and are used as defences
against predators or as ways of killing prey.
Quantitative description of reversible inhibition[edit]
When an enzyme has multiple substrates, inhibitors can show different types
of inhibition depending on which substrate is considered. This results from
the active site containing two different binding sites within the active site,
one for each substrate. For example, an inhibitor might compete with
substrate A for the first binding site, but be a non-competitive inhibitor with
respect to substrate B in the second binding site.[4]